Renowned Expertise at TGH in the Treatment of Irritable Bowel Disease (IBD)

One of the few academic medical centers that specializes in the diagnosis and treatment of irritable bowel disease (IBD), ulcerative colitis, and Crohn's disease, the USF/TGH Inflammatory Bowel Disease Center features a highly specialized team of dedicated IBD experts.

Multidisciplinary Approach to Care

IBD is a complex, niche disease that has immunologic characteristics and often requires care from multiple providers in different specialties. A team of colorectal surgeons, gastroenterologists, nutritionists, as well as a dietitian and social worker participate in monthly case meetings to create specialized care plans for patients with complex IBD-related conditions.

Led By Dedicated IBD Gastroenterologist

IBD Center Director, Dr. Jennifer Seminerio is a fellowship-trained, board-certified gastroenterologists. Her practice is 100% dedicated to the diagnosis, treatment of IBD, as well as research studies to further the field. Dr. Seminerio is a national speaker and recognized IBD expert. She is also host of Florida IBD Live, a CME-accredited Zoom Conference dedicated to educating physicians about IBD treatments and case collaborations.

Robust Research Program

Gastroenterologists at the IBD Center participate in both investigator-initiated and industry clinical trials involving early-stage therapies and medications that may give hope to patients suffering with the most challenging IBD-related diseases. The Center is also home to a fellowship program where physicians learn the latest techniques and technologies to care for this unique set of conditions.

Active Clinical Trials

Corrona-IBD-600 Registry

Monitor patients who have started an approved biologic or JAK inhibitor for the first time within 12 months.

Celgene Ozanimod 3202 Crohn's

For patients with moderate to severely active CD and previous intolerance to corticosteroids, immunomodulators and biologics.

Janssen 3001 UC

For patients with moderate to severely active UC, Mayo rectal bleeding score ≥ 1, screening endoscopy score ≥ 2.


Study patient with postoperative discontinuation of all concomitant medications related specifically to the treatment of CD with laparoscopic ileocecal resection with primary anastomosis within 72 hours before randomization.

Theravance TD-1473 Crohn's

For patients with moderate to severely active CD, previous intolerance to corticosteroids, immunomodulators and biologics.

Tigenix ASC Crohn's

For patients with clinically controlled or mildly active CD, presence of perianal fistula with maximum of 2 internal and 2 external openings, inadequate response to TNF-a antagonist, vedolizumab or ustekinumab.

Eli Lilly AMAM

For patients with moderate to severely active CD, previous intolerance to corticosteroids, immunomodulators and biologics.

Tour Registry

Monitoring patients diagnosed with moderate-severe UC, who within two weeks have been started on tofacitinib or plan to start in the next two weeks.

Inflammatory Bowel Disease Center Receives $1 Million in Funding to Further Patient Care

Using cutting-edge treatment and disease management approaches focused on IBD, the Center actively participates in numerous active clinical trials. A recent funding grant of $1 million will allow Center specialists to continue research and further develop its standing as a center of excellence.